The Trans Pacific Partnership Agreement, intellectual property and medicines
Differential outcomes for developed and developing countries
Bibliographic Data
| ID | 12688692 |
|---|---|
| Authors | Deborah Gleeson (0000-0001-8021-9130, La Trobe University, corresponding author), Joel Lexchin (0000-0001-5120-8029, York University), Ruth Lopert (0000-0002-0882-4288, George Washington University), Burcu Kilic (Public Citizen) |
| Year | 2017 |
| Volume | 18 |
| Issue | 1 |
| Pages | 7-27 |
| Publication date | 2017-10-13 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Global Social Policy (JOURNAL) |
| Journal identifiers | ISSN: 1468-0181 • E-ISSN: 1741-2803 |
| Publisher | SAGE Publishing (PUBLISHER • US) |
| DOI | 10.1177/1468018117734153 |
| PMID | 29706802 |
| OpenAlex | W2765265353 |
| Language | EN |
| Citations received | 15 |
| References cited | 26 |
The final text of the Trans Pacific Partnership Agreement (TPP), agreed between the 12 negotiating countries in 2016, included a suite of intellectual property provisions intended to expand and extend pharmaceutical company exclusivities on medicines. It drew wide criticism for including such provisions in an agreement that involved developing countries (Vietnam, Peru, Malaysia, Mexico, Chile and Brunei Darussalam) because of the effect on delaying the introduction of low-cost generics. While developing nations negotiated transition periods for implementing some obligations, all parties would have eventually been expected to meet the same standards had the TPP come into force. While the TPP has stalled following US withdrawal, there are moves by some of the remaining countries to reinvigorate the agreement without the United States. The proponents may seek to retain as much as possible of the original text in the hope that the United States will re-join the accord in future. This article presents a comparative analysis of the impact the final 2016 TPP intellectual property chapter could be expected to have (if implemented in its current form) on the intellectual property laws and regulatory regimes for medicines in the TPP countries. Drawing on the published literature, it traces the likely impact on access to medicines. It focuses particularly on the differential impact on regulatory frameworks for developed and developing nations (in terms of whether or not legislative action would have been required to implement the agreement). The article also explores the political and economic dynamics that contributed to these differential outcomes
Business · Criticism · Developing country · Differential (mechanical device · Differential treatment · Economic growth · Economics · General partnership · Intellectual property · International trade · Law and economics · Legislature · Negotiation · Political science · Politics · Engineering · Health Systems, Economic Evaluations, Quality of Life · Intellectual Property and Patents · Law · Pharmaceutical Economics and Policy
Global Health Trade Summit
Public health clauses in international investment agreements
Assessing public health implications of free trade agreements
Ticaret Savaşları mı, Küresel Kapitalizmin Regülasyon Açmazı mı? Uluslararası Ticaret Anlaşmaları Kimin için
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines
Moderating the impact of patent linkage on access to medicines
The potential impact of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership on Thailand’s hepatitis C treatment program
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
Analyzing the impact of trade and investment agreements on pharmaceutical policy
Special Issue on trade and health
Rights, regulation and redistribution
India’s Distinct but Opposing Patent Model Is Under Pressure
Power and innovative capacity
Glossary on free trade agreements and health part 2
How do actors with asymmetrical power assert authority in policy agenda-setting? A study of authority claims by health actors in trade policy
Improving regulatory capacity to manage risks associated with trade agreements
Ceta and pharmaceuticals
Investments in Pharmaceuticals Before and After TRIPS
The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam
Policy coherence, health and the sustainable development goals
The political economy of the Trans-Pacific Partnership
Global value chains and development
| Unique citing works | 15 |
|---|---|
| Citations per year | 1.88 |
| Citation span | 2018 - 2025 (8) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 15 |